Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinomaopen access
- Authors
- Jang, Hong Seok; Kang, Ki Mun; Choi, Byung Ock; Chai, Gyu Young; Hong, Soon Chan; Ha, Woo Song; Jirtle, Randy L.
- Issue Date
- 7-Mar-2008
- Publisher
- BAISHIDENG PUBLISHING GROUP INC
- Keywords
- loss of heterozygosity; mannose 6-phosphate/insulin-like growth factor 2 receptor; hepatocellular carcinoma
- Citation
- WORLD JOURNAL OF GASTROENTEROLOGY, v.14, no.9, pp.1394 - 1398
- Indexed
- SCIE
SCOPUS
- Journal Title
- WORLD JOURNAL OF GASTROENTEROLOGY
- Volume
- 14
- Number
- 9
- Start Page
- 1394
- End Page
- 1398
- URI
- https://scholarworks.bwise.kr/gnu/handle/sw.gnu/27471
- DOI
- 10.3748/wjg.14.1394
- ISSN
- 1007-9327
- Abstract
- AIM: To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy. METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy. RESULTS: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03). CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients. (c) 2008 WJG. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.gnu.ac.kr/handle/sw.gnu/27471)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.